Spliceosomal peptide P140 clinical trials
Also written Lupuzor and CEP-33457.
How each study uses spliceosomal peptide P140 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Cephalon, Inc. (2) · ImmuPharma (1)
Studies
Open first, then newest update. How each study uses spliceosomal peptide P140 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus ErythematosusTerminatedPhase 3Cephalon, Inc.NCT01240694Written as CEP-33457
- A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)CompletedPhase 2Cephalon, Inc.NCT01135459Written as CEP-33457
- Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus ErythematosusCompletedPhase 3ImmuPharmaNCT03427151Written as IPP-201101
As the comparator · 1 — what is tested is compared with spliceosomal peptide P140
Codes
What other systems call spliceosomal peptide P140 · ClinicalTrials.gg INT005387
Also registered as forigerimod (UNII 1JRB6UKG4Q) and forigerimod acetate (UNII YU54FAR97X).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.